Texas 2021 - 87th Regular

Texas House Bill HB3922 Compare Versions

OldNewDifferences
11 87R21298 KKR-F
22 By: Oliverson H.B. No. 3922
3+ Substitute the following for H.B. No. 3922:
4+ By: Oliverson C.S.H.B. No. 3922
35
46
57 A BILL TO BE ENTITLED
68 AN ACT
79 relating to information provided by health care providers and
810 hospitals to certain patients regarding pharmaceutical
911 manufacturer patient assistance programs for insulin.
1012 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
1113 SECTION 1. Subchapter N, Chapter 531, Government Code, is
1214 amended by adding Section 531.509 to read as follows:
1315 Sec. 531.509. INFORMATION ON PHARMACEUTICAL MANUFACTURER
1416 PATIENT ASSISTANCE PROGRAMS FOR INSULIN. (a) This section applies
1517 to health care providers and hospitals that receive uncompensated
1618 care pool payments from the commission, including:
1719 (1) federally qualified health centers as defined by
1820 42 U.S.C. Section 1396d(l)(2)(B);
1921 (2) rural health clinics as defined by 42 U.S.C.
2022 Section 1396d(l)(1); and
2123 (3) physician group practices.
2224 (b) A health care provider or hospital to which this section
2325 applies shall provide to patients who have diabetes and require
2426 insulin information regarding the availability of pharmaceutical
2527 manufacturer patient assistance programs, including copay cards,
2628 that may reduce the cost of insulin to the patients.
2729 (c) The executive commissioner shall adopt rules to
2830 implement this section.
2931 SECTION 2. If before implementing any provision of this Act
3032 a state agency determines that a waiver or authorization from a
3133 federal agency is necessary for implementation of that provision,
3234 the agency affected by the provision shall request the waiver or
3335 authorization and may delay implementing that provision until the
3436 waiver or authorization is granted.
3537 SECTION 3. This Act takes effect September 1, 2021.